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Introduction: Unstable atherosclerotic plaques are prone to rupture, which leads to atherothrombosis. Endothelial
progenitor cells (EPCs) are bone marrow-derived precursor cells that may repair vascular injury in atherosclerosis.
Chemokine (C-C motif) receptor 5 (CCR5) promotes mobilization of EPCs. In this study, we investigated the therapeutic
potential of CCR5-overexpressing EPCs on plaque stabilization in an apolipoprotein E (ApoE)−/− mouse model.
Methods: The expression of CCR5 and its cognate ligand chemokine (C-C motif) ligand 5 (CCL5) was examined in
atherosclerotic aortas of humans and mice by immunohistochemistry. Splenectomized ApoE−/− C57BL/6 J mice fed a
high-fat diet for 24 weeks were intravenously injected with EPCs transfected with CCR5 overexpression lentivirus. The
recruitment of EPCs over the atherosclerotic plaques was evaluated by immunofluorescence. The content of lipid,
smooth muscle cells, monocytes/macrophages, and endothelial cells in atherosclerotic plaques was assayed by specific
immunostaining. The serum levels of atherosclerosis-related inflammatory factors in ApoE−/− mice were measured by
mouse atherosclerosis antibody array I.
Results: CCR5 and CCL5 are highly expressed in atherosclerotic plaques in both humans and mice. The ApoE−/− mice
with CCR5-overexpressing EPC treatment demonstrated a more stable plaque formation with enhanced recruitment of
EPC, reduced lipid, and macrophage content in the atherosclerotic plaques. CCR5-overexpressing EPC treatment also
increased the content of endothelial cells and nitric oxide production in the plaques. In addition, the serum levels of
interleukin-3 (IL-3), IL-5, IL-6, IL-13, CD40, and tumor necrosis factor-alpha and the plaque contents of IL-6 and matrix
metalloproteinase-9 were reduced in mice with CCR5-overexpressing EPC treatment.
Conclusions: These findings suggest that CCR5 is a novel therapeutic target in EPC treatment for stabilization of
atherosclerotic plaques.Introduction
Atherothrombotic events, such as myocardial infarction
and strokes, are the most devastating clinical manifesta-
tions of atherosclerosis [1,2]. The leading cause of ath-
erothrombosis is atherosclerotic plaque rupture [1,2],
which is characterized by injury of endothelium and ex-
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unless otherwise stated.The current treatments are limited in their overall effect-
iveness. The lipid-lowering and anti-platelet drug treat-
ments are not sufficient to stabilize vulnerable plaques,
and intervention therapies might result in re-narrowing
[3]. Thus, it is crucial to find new approaches to reduce
atherosclerotic plaque rupture, and eventually reduce the
disease burden.
Endothelial cells (ECs) play a crucial role in the forma-
tion and stabilization of atherosclerotic plaques [1-4].
High cholesterol, high blood pressure, or diabetes induces
EC dysfunction and damages the integrity of the endothe-
lium. Circulating low-density lipoprotein cholesterol
crosses the damaged endothelium and accumulates in the
wall of the artery, initiating the plaque formation [5]. Dur-
ing the development of atherosclerotic plaques, apoptosisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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core, loss of collagen, and intimal inflammation [3,4].
Endothelial progenitor cells (EPCs) are a type of bone
marrow (BM)-derived precursor cells that can differen-
tiate ex vivo to an endothelial phenotype [3,4,6]. Upon
EC dysfunction, EPCs from BM move into the circula-
tion and replace the damaged cells [3,4,6-8]. However,
mobilization of EPCs from BM to the atherosclerotic
plaques is very limited in non-treatment conditions [9].
Thus, interventions improving EPC recruitment may
present a novel strategy for plaque stabilization.
Chemokine receptor 5 (CCR5) is a member of the β-
chemokine receptor family and a G-coupled seven-trans-
membrane chemokine receptor [10]. CCR5 is expressed in
leukocytes and monocytes/macrophages [11]. Genetic in-
activation of CCR5 is associated with the reduction of pro-
atherogenic cytokines and the accumulation of monocytes/
macrophages in atherosclerotic plaques [12,13]. CCR5’s cog-
nate ligand chemokine ligand 5 (CCL5), also known as
RANTES (regulated on activation, normal T cell expressed
and secreted), is a member of the CC-chemokine family
stored in and released from platelets and activated T cells
[14]. CCL5 is upregulated in the injured vessels via activa-
tion by platelets during the process of atherosclerosis [9,15].
Increased expression of CCL5 on the surface-adherent
platelets mediates trafficking of monocytes/macrophages
into injured vessels by binding with its receptor CCR5
[10,12,13]. To date, the effects of CCR5 on the stability of
atherosclerotic plaques have not been addressed. Recent
studies reported that CCR5 mediates glomerular micro-
vascular endothelial regeneration by stimulating the adhe-
sion of BM-derived EPCs [14] and that inhibition of CCR5
expression reduces EPC recruitment during wound healing
in mice [16]. Thus, we hypothesize that increased expres-
sion of CCR5 in EPCs may enhance the stability of plaques
by stimulation of EPC mobilization and recruitment.
In this study, we examined the role of CCR5 in EPCs on
atherosclerotic plaques by injection of CCR5-overexpressing
EPCs into the ApoE−/− mice and evaluation of plaque stabil-
ity in these mice. We found that overexpression of CCR5 in
EPCs enhanced the accumulation of EPCs over atheroscler-
otic plaques. In addition, CCR5-overexpressing EPC treat-
ment decreased the macrophage content on advanced
atherosclerotic plaques. Our findings indicate that over-
expression of CCR5 improves EPC treatment for the
stabilization of atherosclerotic plaques.
Methods
Animals
ApoE−/− C57BL/6 J male mice were purchased from Vital
River (Beijing, China). All animal studies were performed
at the Animal Care Center of the Key Laboratory of Car-
diovascular Remodeling and Function Research, Shandong
University (Shandong, China). The animal experimentsfollowed the Regulation of Animal Care Management of
the Ministry of Public Health, People’s Republic of China
(document 55, 2001) and were approved by the Ethical
Committee of Shandong University.
Splenectomy surgery
The spleens of the mice were dissected as previously de-
scribed [17,18]. In brief, mice (8 to 10 weeks old) were
anesthetized with intraperitoneal administration of 0.8%
pentobarbital sodium (10 mg/kg body weight). An incision
of 10 to 15 mm was made above the left abdomen of each
mouse, and the spleen was removed after cauterizing the
splenic arteries and venous supply. The mice were allowed
to recover for 7 days before further treatment.
Isolation and culture of mouse endothelial progenitor
cells
EPCs were isolated from 8-week-old male C57 mice. In
brief, whole BM cells were collected under sterile condi-
tions from femur (and tibias) by flushing the shaft with
phosphate-buffered saline (PBS). The mononuclear cells
were isolated by percoll density gradient centrifugation
(Sigma-Aldrich, St. Louis, MO, USA) at 2,000 g for
20 minutes. After three rinses, the isolated cells were
cultured in endothelial basal medium-2 (EBM-2) with
an MV Bullet Kit (Lonza, Walkersville, MD, USA). After
7 days of culture, the EPC markers DiI-labeled acetylated
low-density lipoprotein (DiI-AcLDL) (Sigma-Aldrich) and
bandeiraea simplicifolia lectin 1 (BS-1 lectin) (Sigma-
Aldrich) were confirmed by immunofluorescence analysis.
Preparation of lentivirus vectors and endothelial
progenitor cell infection
The recombinant lentiviruses (Lenti) carrying murine
CCR5 (Lenti-EGFP-CCR5) or a control transgenic EGFP
(Lenti-EGFP) were prepared as previously described [19].
Passage 2 of EPCs was used for lentivirus transfection.
Prior to transfection, cultured EPCs were labeled with
CM-DiI (4 mg/mL; Molecular Probes, Eugene, OR, USA)
for 15 minutes in accordance with the protocol of the
manufacturer. Then the EPCs were incubated in EBM-2
containing Lenti-EGFP-CCR5 or Lenti-EGFP particles.
The lentiviral particles were removed after 24 hours. The
double-labeled EPCs were harvested (passage 3) and re-
suspended at 1 × 106 cells/mL in PBS for administration
to the mice.
Experimental design
Sixty splenectomized ApoE−/− mice were treated with a
high-fat, high-cholesterol diet (21% anhydrous milk fat/but-
ter fat, 34% sucrose and 0.2% cholesterol; Teklad; Harlan
Laboratories, Indianapolis, IN, USA) for 24 weeks. Then
the animals were randomly divided into three groups and
intravenously injected with 200 μL of sterile PBS (control
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Lenti-EGFP (Lenti-EGFP group) or 200 μL of 1 × 106/mL
EPCs infected with Lenti-EGFP-CCR5 (Lenti-CCR5 group).
After treatment, all mice were returned to normal chow
diet for the remaining experiments.
Quantification and morphometry of atherosclerotic lipid
deposition
After treatments, 15 mice in each group were sacrificed
and aortas were isolated after saline perfusion to prepare
frozen sections as described previously [13,15,17,18]. The
plaque areas were measured in four subsequent sections
for each mouse, and each section included three segments
[18]. The images of the sections were captured with a
digital camera (Canon, Tokyo, Japan) and analyzed by
Image-Pro Plus Software (Media Cybernetics, Silver Spring,
MD, USA). The aortic sinus frozen sections were stained
with Oil Red O (Sigma-Aldrich), and the positive staining
area was used to quantitate the atherosclerotic plaque area
[19,20].
Human ascending aorta samples were obtained from the
Department of Pathology of Qianfoshan Hospital. The pla-
ques were classified for progression stages (early, advanced
stable, and advanced unstable) as described previously [21].
All of the studies were performed in accordance with the
‘Code for Proper Secondary Use of Human Tissue’ and ap-
proved by the Ethical Committee of Shandong University.
All donors provided written informed consent.
Immunohistochemistry and immunofluorescence
Immunohistochemical assays were performed with the
following primary antibodies: rabbit anti-α smooth muscle
actin (1:150 dilution; Abcam, Cambridge, MA, USA), rat
anti-Monocyte +Macrophage (MOMA-2, 1:100 dilution;
Abcam), rat anti-CD31 (1:150 dilution; BD Biosciences,
San Diego, CA, USA), goat anti-CCL5/RANTES (1:25 di-
lution; Santa Cruz Biotechnologies, Dallas, TX, USA), goat
anti-CCR5 (1:25 dilution; Santa Cruz Biotechnologies),
rabbit anti-IL-6 (1:500 dilution; Abcam), and rabbit anti-
MMP9 (1:250 dilution; Abcam). Secondary antibodies
used in these assays were purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA,
USA). The reaction was visualized by staining with 3,
3-diaminobenzidine (DAB) (Abcam). The ECs were
identified by anti-CD31 antibody, and the staining
intensity was evaluated as described previously [22]. The
staining intensity is rated on a scale of 0 to 3: 0 = negative,
1 = weak, 2 =moderate, and 3 = strong. The accumulation
of EPCs over the atherosclerotic plaques was evaluated by
immunofluorescence analysis. In brief, double-labeled
EPCs (EGFP and CM-DiI) were transplanted into the
ApoE−/− mice, and the mice were sacrificed on weeks 1
and 6 after transplantation. The aortic roots were excised,
and 6-μm frozen sections were prepared as describedpreviously [13,17,18]. The frozen sections were stained
with 4′, 6-diamidino-2-phenylindole (DAPI) for 5 minutes.
The number of triple-color positive cells (EGFP+, DiI+,
and DAPI+) on atherosclerotic plaques was counted in
three randomly chosen high-power fields (magnification,
200×), and representative results from three independent
experiments are shown. To examine the incorporation of
labeled putative EPCs into endothelium, the cross-sections
of aortic roots of ApoE−/− mice treated with EPCs were
stained with primary rat anti-mouse CD31 (BD Biosciences,
San Jose, CA, USA) or control rat IgG2a Ab (Abcam) and
secondary donkey anti-rat Alexa Fluor 594 Ab (Life
Technologies, Grand Island, NY, USA).
Immunochemistry
Venous blood samples of the mice were collected 0, 1,
and 6 weeks after treatment and centrifuged to collect
the serum. Inflammatory cytokines were assessed by a
mouse atherosclerosis antibody array I (RayBiotech Inc.,
Norcross, GA, USA), which consists of 22 antibodies for
atherosclerosis-related cytokines. The Cluster version
3.0 and Java TreeView version 1.60 software (Michael
Eisen’s lab) were used to analyze the results as described
previously [23]. Fold change (FC) was used to identify
genes with large shifts between the control group and
treatment group [24]. Serum nitrite and nitrate were
measured by a colorimetric nitric oxide (NO) metabolite
detection kit (Cayman Chemical Company, Ann Arbor,
MI, USA).
Migration and proliferation assays
The migration of EPCs was evaluated by using transwell
chambers (Costar Corp., Cambridge, MA, USA). In brief,
mouse EPCs were resuspended at 5 × 104 cells/100 μL in
serum-free EBM-2 and seeded in the upper chambers.
Recombinant mouse CCL5 (100 μg/mL; R&D Systems,
Minneapolis, MN, USA), CCL5 (100 μg/mL) combined
with anti-CCL5 antibody (6 μg/mL; Abcam), or EBM-2
was added into the lower chambers. After 24 hours,
the number of EPCs migrated into lower chambers
was counted manually in three randomly chosen
high-power fields (magnification, 100×) per filter. The
proliferation of EPCs was examined by using a
5-ethynyl-2′-deoxeuridine (EdU) assay kit (RiboBio
Co., Ltd, Wuhan, China). EPCs were resuspended at
1 × 104 cells/100 μL in serum-free EBM-2 and seeded
in the 96-well plate (Costar Corp.) containing 50 nM
EdU per well. After 72 hours, EPCs were fixed with
4% paraformaldehyde and subsequently incubated with
100 μL of 1× EdU staining liquid for 30 minutes. The
DNA contents of EPCs were stained with DAPI
(Sigma-Aldrich) for 5 minutes, and the EdU-positive
cells were counted under a fluorescence microscope
(IX-71; Olympus, Tokyo, Japan).
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Statistical differences between groups were examined by
one-way analysis of variance with Mann-Whitney U test.
A P value of less than 0.05 was considered statistically
significant. All statistical analyses were performed by
using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA).
Results
Expression of CCL5 and CCR5 during progression of
atherosclerotic plaques in humans and mice
The expression of CCL5 in ascending atherosclerotic aorta
of patients with atherosclerosis was examined by immuno-
histochemistry. As shown in Figure 1, the positive staining
of CCL5 was observed in the arteries of the patients with no
visible atherosclerotic plaques (intima, 9.93%± 4.57%; media,
0.43% ± 0.29%; adventitia, 17.91%± 2.66%), arteries of the
patients with atherosclerotic plaques (intima, 22.18% ±
3.37%; media, 23.87% ± 5.04%; adventitia, 28.31%± 4.42%),
and arteries of the patients with advanced unstable plaques
(intima, 23.38% ± 3.23%; media, 22.42% ± 9.02%; adventitia,
43.37% ± 0.67%). Quantitative image analysis indicated a sig-
nificant increase of CCL5 expression in the intima and
media of the patients with advanced unstable plaques in
comparison with those with no visible atherosclerotic pla-
ques (intima, P <0.05; media, P <0.01). However, no signifi-
cant difference was found between the arteries of the
patients with advanced unstable plaques and the arteries of
the patients with atherosclerotic plaques (intima, P= 0.64;
media, P = 0.81). CCL5 expression in the adventitia was sig-
nificantly increased in the arteries of the patients withFigure 1 CCL5 expression in ascending aorta of humans and mice. (A) Imm
unstable plaques of human samples. (B) Quantitative analysis of CCL5 expression
non-diseased artery, advanced plaques, and unstable plaques of ApoE−/− mice. (D
Bars represent mean± standard deviation. ApoE, apolipoprotein E; CCL5, chemok
hemorrhage (advanced unstable plaques); ND, non-diseased arteries; n.s., non-sigadvanced unstable plaques in comparison with those with
atherosclerotic plaques or no visible atherosclerotic plaques
(P <0.05 and P <0.01, respectively).
CCL5 expression was also examined in ApoE−/− mice fed
a high-fat diet. As shown in Figure 1C, the positive staining
area of CCL5 was observed in the arteries of the mice with
no visible atherosclerotic plaques (intima, 20.23% ± 2.35%;
media, 19.86% ± 4.75%; adventitia, 3.15% ± 0.30%), arteries
of the mice with atherosclerotic plaques (intima, 33.09% ±
3.91%; media, 14.41% ± 4.21%; adventitia, 3.33% ± 0.30%),
and arteries of the mice with advanced unstable plaques
(intima, 17.43% ± 2.22%; media, 36.73% ± 0.45%; adventitia,
13.5% ± 1.41%). We found a significant decrease of CCL5
expression in the intima of the mice with advanced un-
stable plaques in comparison with those with atheroscler-
otic plaques (P <0.01). However, there were no significant
differences between the arteries of the mice with advanced
unstable plaques and the arteries of the mice with no visible
atherosclerotic plaques (P = 0.20). CCL5 expression was sig-
nificantly increased in the media of the mice with advanced
unstable plaques in comparison with those with athero-
sclerotic plaques or no visible atherosclerotic plaques
(P <0.01 and P <0.05, respectively). In the adventitia, the
expression of CCL5 was significantly increased in the arter-
ies of the mice with advanced unstable plaques in compari-
son with those with atherosclerotic plaques or no visible
atherosclerotic plaques (P <0.01 and P <0.01, respectively).
In addition, we examined the expression of CCR5 in as-
cending aorta of humans and mice. CCR5 protein was
faintly detected in non-diseased artery and was highlyunohistochemistry of CCL5 in non-diseased artery, advanced plaques, and
in (A) (n = 3, *P <0.05, **P <0.01). (C) Immunohistochemistry of CCL5 in
) Quantitative analysis of CCL5 expression in (C) (n = 3, *P <0.05, **P <0.01).
ine (C-C motif) ligand 5; IPH, thin capped fibroatheroma with intraplaque
nificant; TfcA, thick fibrous cap atheroma (advanced stable plaques).
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mice. (Additional file 1 shows this in more detail.)
Overexpression of CCR5 increased endothelial progenitor
cell recruitment to atherosclerotic plaques
To investigate the effects of CCR5 overexpression on EPCs,
CM-DiI-labeled EPCs were transfected by lentivirus
encoded with EGFP (Lenti-EGFP) or EGFP-CCR5 (Lenti-
CCR5) gene. The efficiency of the transfection in EPCs was
evaluated by immunofluorescence, and more than 80%
EPCs transfected with lentivirus vectors are positive for
EGFP, indicating that EPCs with EGFP or EGFP-CCR5 ex-
pression were successfully established. (Additional file 2A
shows this in more detail.) Western blot analysis displayed
that the protein level of CCR5 was remarkably higher in the
cells of the Lenti-CCR5 group than those of Lenti-EGFP
group (Additional file 2). These transfected cells were intra-
venously injected into the ApoE−/− mice treated with a
high-fat diet for 24 weeks. To examine incorporation of la-
beled putative EPCs into endothelium, the cross-sections of
aortic roots of ApoE−/− mice treated with EPCs were stained
with the antibody for CD31, the EC-specific marker. As
shown in Figure 2, EPCs (EGFP+) were localized in the
endothelium of the atherosclerotic plagues, suggesting that
EPCs successfully engrafted in the vascular wall. EPCs
(EGFP+) were also found in the sub-endothelial region of
the atherosclerotic plagues in the Lenti-CCR5 group. In
addition, the number of triple-color labeled EPCs detected
in the atherosclerotic plaques of the Lenti-CCR5 group is
significantly higher than that of the Lenti-EGFP group
1 week (13.5 ± 1.1 versus 6.5 ± 0.7, P <0.05) and 6 weeks
post-treatment (13.0 ± 1.4 versus 2.3 ± 0.5, P <0.01), suggest-
ing that CCR5 overexpression enhanced recruitment of
EPCs over the atherosclerotic plaques.
Since EPCs may translocate into non-target organs of the
mice after intravenous injection, we examined lung andFigure 2 Overexpression of CCR5 in endothelial progenitor cells (EPCs) p
(A) Representative images of EPC incorporation on atherosclerotic plaques 6 we
overexpression of EPC treatment (Lenti-CCR5). DAPI (blue), EGFP (green), CD31 (
EPCs on atherosclerotic plaques in Lenti-EGFP and Lenti-CCR5 groups (*P <0.05,
was counted from three randomly chosen high-power fields (magnification, 200
receptor 5; DAPI, 4′, 6-diamidino-2-phenylindole; EGFP, enhanced green fluorescliver to track the transplanted EPCs. Immunofluorescence
staining showed that transplanted EPCs were detected in
liver but not in lungs, and the numbers of EPCs recruited
in the liver were similar between the Lenti-EGFP group
and the Lenti-CCR5 group (data not shown).
CCR5-overexpressing endothelial progenitor cell
treatment enhanced stability of plaques
To assess the effects of CCR5 overexpression EPC treat-
ment on the stabilization of atherosclerotic plaques, we
examined surrogate markers for plaque stability, including
lipid burden, smooth muscle cells (SMCs), and monocyte/
macrophage (MOMA-2) content in the plaques by immu-
nostaining. Six weeks after the treatment, the plaques in
the Lenti-CCR5 group (9.58% ± 1.51%) displayed a sub-
stantial regression in overall plaques area compared with
the Lenti-EGFP (18.72% ± 2.52%) or the control group
(19.75% ± 2.98%) as quantified by Oil Red O staining of
the aortic sinus (Figure 3A, B). Quantitative image analysis
showed a significant decrease in the positive staining area
of MOMA-2 in the Lenti-CCR5 group (2.56% ± 0.94%)
compared with the Lenti-EGFP group (7.76% ± 2.37%,
P <0.05) or the control group (11.4% ± 1.78%, P <0.01).
However, no significant difference was found for the
plaque contents of SMCs between the Lenti-CCR5
(P = 0.76) or Lenti-EGFP (P = 0.97) group and the control
group (Figure 3A, C). In summary, treatment with CCR5-
overexpressing EPCs reduces lipid deposition and macro-
phage invasion in ApoE−/− mice.
CCR5-overexpressing endothelial progenitor cell
treatment improved endothelial dysfunction of the
atherosclerotic plaques
Endothelial dysfunction is an independent predictor for
atherothrombosis progression and is associated with
plaque instability [25]. To investigate whether the CCR5-romoted the recruitment of EPCs into atherosclerotic plaques.
eks after phosphate-buffered saline (PBS), EPC (Lenti-EGFP), and CCR5
red). Arrowheads indicate EPCs (EGFP+). (B) Quantitative analysis of migrated
**P <0.01). The average number of EGFP+ EPCs on atherosclerotic plaques
×). Bars represent mean ± standard deviation. CCR5, chemokine (C-C motif)
ent protein.
Figure 3 The effects of CCR5-overexpressing endothelial progenitor cell treatment on plaque composition. (A) Staining for the lipids, monocytes/
macrophages (MOMA-2), and smooth muscle cells (SMCs) in control group, Lenti-EGFP group, and Lenti-CCR5 group of mice. Arrowheads indicate positive
staining areas. (B) Ratio of Oil Red-positive staining area to aorta lumen area in control group, Lenti-EGFP group, and Lenti-CCR5 group of mice (n = 6,
**P <0.01). (C) Quantitative analysis of the plaque composition of MOMA-2 and SMCs (n = 6, *P <0.05, **P <0.01). Bars represent mean ± standard deviation.
CCR5, chemokine (C-C motif) receptor 5; EGFP, enhanced green fluorescent protein; n.s., non-significant.
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in ApoE−/− mice, we examined plaque content of ECs and
the level of the serum NO, a molecule with protective ef-
fects in atherosclerosis. As shown in Figure 4, immunohis-
tochemistry revealed a moderate to strong CD31+ staining
in ascending arteries of the Lenti-CCR5 group on weeks 1
and 6 post-treatment. The CD31+ staining in ascending
arteries of the Lenti-EGFP group was uniformly lower
than in that of the Lenti-CCR5 group. In addition, serum
NO level was remarkably higher in the Lenti-CCR5 group
than in the Lenti-EGFP group as detected by colorimetric
analysis (42.3 ± 1.8 versus 36.6 ± 2.8, P <0.05, Figure 5).
CCR5-overexpressing endothelial progenitor cell
treatment reduced pro-inflammatory factors in circulation
and atherosclerotic plaques
Vascular inflammation is one of major causes of plaque
rupture. We evaluated the serum levels of atherosclerosis-
related inflammatory factors in mice treated with CCR5-
overexpressing EPCs using mouse atherosclerosis antibody
array I. Six weeks after treatment, nine proteins were identi-
fied with significant fold changes according to the heatmap
diagram (Figure 6A). Among them, interleukin 6 (IL-6), IL-
5, IL-3, IL-13, CD40, and tumor necrosis factor-alpha
(TNF-α) were decreased in the Lenti-CCR5 group.Granulocyte-macrophage colony-stimulating factor (GM-
CSF), macrophage inflammatory protein-3α (MIP-3α), and
basic fibroblast growth factor (bFGF) were slightly in-
creased in the Lenti-CCR5 group. The IL-6 level was de-
clined by roughly 50% in the Lenti-CCR5 group compared
with that in control group (Figure 6B, C). The plaque con-
tent of IL-6 was further examined by immunostaining.
As shown in Figure 7A and B, the positive staining area
of IL-6 in the media of arteries was significantly decreased
in the Lenti-CCR5 group in comparison with that in the
Lenti-EGFP or control group (Lenti-CCR5 versus Lenti-
EGFP, 13.07% ± 2.11% versus 24.3% ± 4.85%, P <0.05; Lenti-
CCR5 versus control, 13.07% ± 2.11% versus 34.03% ±
6.15%, P <0.01). However, no significant difference was
found in the intima of arteries between the Lenti-CCR5
group (P = 0.34) or the Lenti-EGFP group (P = 0.06) and
the control group. Matrix metalloproteinase 9 (MMP9)
plays an essential role in local proteolysis of the extra-
cellular matrix (ECM) [26]. Degradation of ECM com-
ponents by MMP9 induces plaque inflammation and
promotes plaque instability [27]. Thus, we examined the
plaque content of MMP9 by immunostaining. As shown
in Figure 7C and D, the positive staining area of MMP9
was significantly decreased in the media of arteries in
the Lenti-CCR5 group in comparison with that in the
Figure 4 CCR5-overexpressing endothelial progenitor cell
treatment improved endothelial cell content. (A) CD31 staining in
coronary artery of control group, Lenti-EGFP group, and Lenti-CCR5 group
of mice 1 week after treatment. (B) CD31 staining in coronary artery of
control group, Lenti-EGFP group, and Lenti-CCR5 group of mice 6 weeks
after treatment. Arrows refer to the endothelium of the luminal side of the
coronary arteries. CCR5, chemokine (C-C motif) receptor 5; EGFP, enhanced
green fluorescent protein.
Figure 5 CCR5-overexpressing endothelial progenitor cell
treatment increased serum nitric oxide (NO). The serum NO
level of ApoE−/− mice at baseline and 6 weeks after treatment with
phosphate-buffered saline, Lenti-EGFP, and Lenti-CCR5 (n = 6, *P <0.05;
n = 6). Bars represent mean ± standard deviation. ApoE, apolipoprotein
E; CCR5, chemokine (C-C motif) receptor 5; EGFP, enhanced green
fluorescent protein; n.s., non-significant.
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EGFP, 16.26% ± 2.14% versus 23.57% ± 0.45%, P <0.01;
Lenti-CCR5 versus control, 16.26% ± 2.14% versus
30.34% ± 2.57%, P <0.01). In the intima, there is no sta-
tistically significant difference between the Lenti-CCR5
and Lenti-EGFP groups (27.41% ± 1.92% versus 23.42%
± 4.58%, P = 0.23). However, significantly increased
MMP9 expression was found in the Lenti-CCR5 group
in comparison with that in the control group (27.41% ±
1.92% versus 10.07% ± 3.28%, P <0.01). Thus, MMP9 is
increased in the intima but decreased in the media in
atherosclerotic plaque with CCR5-overexpressing EPC
treatment.CCL5/CCR5 interaction involved in endothelial progenitor
cell migration
Previous study showed that CCL5 significantly induced
cell migration [16]. To confirm whether CCL5 interacts
with CCR5 to promote the migration of EPCs, we
performed in vitro chemotaxis assays with CCR5-
overexpressing EPCs. As seen in Figure 8, CCL5 signifi-
cantly enhanced the migration of EPCs in the Lenti-CCR5
group in comparison with the Lenti-EGFP group
(P <0.01). After the addition of anti-CCL5 antibody, the
numbers of migrated EPCs in the Lenti-EGFP group and
Lenti-CCR5 group were similar (P = 0.04), suggesting that
CCR5 overexpression induced EPC migration operates in
a CCL5-dependent manner. Furthermore, we examined
EPC proliferation by EdU incorporation (Figure 8C, D),
and the cell growth was similar between the Lenti-CCR5
group and the Lenti-EGFP group (P = 0.98). Thus, overex-
pression of CCR5 promotes migration of EPCs without af-
fecting their proliferation.
Discussion
Chemokines are crucial for atherosclerotic progress
[13,28,29]. In this study, we found that chemokine CCL5
was upregulated in advanced atherosclerotic plaques and
generated EPCs overexpressing CCR5. These CCR5-
overexpressing EPCs were injected into ApoE−/− mice and
induced a phenotype of more stable atherosclerotic pla-
ques in these mice. In addition, we found that overexpres-
sion of CCR5 in EPCs contributes to endothelial repair
and reduces pro-inflammatory cytokines.
Circulating EPCs may differentiate ex vivo into ECs
[7,30] and improve EC regeneration in a variety of arterial
Figure 6 Hierarchical clustering analysis of pro-inflammatory factors. (A) The rows represent treatment groups, and the columns represent
inflammatory factors. Red, black, and green colors indicate upregulation, unchanged expression, and downregulation compared with spike-in control. The
color bars correspond to the relative expression level of inflammatory factors. (B, C) Fold changes were further analyzed for upregulation and downregulation
of protein expression in (A). bFGF, basic fibroblast growth factor; EGFP, enhanced green fluorescent protein; G-CSF, granulocyte colony-stimulating factor;
GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-gamma; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; M-CSF,
macrophage colony-stimulating factor; MIP-3α, macrophage inflammatory protein-3α; RANTES, regulated on activation, normal T cell expressed and secreted;
TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.
Figure 7 CCR5-overexpressing endothelial progenitor cell treatment decreased interleukin-6 (IL-6) and matrix metalloproteinase 9 (MMP9)
expression on the atherosclerotic plaques. (A) Immunostaining of IL-6 on the aortic root plaques at 6 weeks after treatment with phosphate-buffered
saline (PBS), Lenti-EGFP, or Lenti-CCR5. (B) Quantitative analysis of the IL-6 expression in (A) (n = 6, *P <0.05, **P <0.01). (C) Immunostaining of MMP9 on the
aortic root plaques at 6 weeks after treatment with PBS, Lenti-EGFP, or Lenti-CCR5. (D) Quantitative analysis of the MMP9 expression in (C) (n = 6, *P <0.05,
**P <0.01). Bars represent mean ± standard deviation. CCR5, chemokine (C-C motif) receptor 5; EGFP, enhanced green fluorescent protein; n.s., non-significant.
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Figure 8 Effects of CCL5 and CCR5 interaction on endothelial progenitor cell (EPC) migration and proliferation. (A) Transwell migration assay of
EPCs after transfection with Lenti-EGFP or Lenti-CCR5. (B) Quantitative analysis of the results in (A) (n = 3, *P <0.05, **P <0.01). (C) Representative images of
5-ethynyl-2′-deoxeuridine (EdU) cell proliferation after transfection with Lenti-EGFP or Lenti-CCR5. Arrows indicate EdU-positive cells. (D) Rate of EdU-positive
cells in (C) (n = 3). Bars represent mean± standard deviation. CCL5, chemokine (C-C motif) ligand 5; CCR5, chemokine (C-C motif) receptor 5; DAPI,
4′, 6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein; n.s., non-significant.
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ment to the injury sites are not clear [35,36]. The chemokine
receptor CCR5 is detected in EPCs, and CCR5-mediated
signals may be involved in EPC recruitment from circulation
to injured vascular wall [14,16]. In this study, we created a
Lentivirus expression system to overexpress CCR5 in EPCs
and injected these cells into ApoE−/− mice. We demon-
strated that CCR5 overexpression increased the number of
EPCs recruited to atherosclerotic plaques and that CCR5-
overexpressing EPCs enhanced the plaque stability. These
observations indicated that CCR5 is involved in EPC recruit-
ment and the stabilization of atherosclerotic plaques. In
addition to CCL5/CCR5, other chemokines stabilize athero-
sclerotic plaques. For example, CXCL12 promotes the
stabilization of atherosclerotic plaques by increasing the re-
cruitment of smooth muscle progenitor cells to the plaques
in ApoE−/− mice [37]. The CXCL1-CXCR2 axis is required
for the recruitment of BM EPCs to the plaques [19,38].
Taken together, specific chemokines mediate mobilization of
progenitor cells to sites of atherosclerotic plaques and pro-
mote plaque stability.
EC function is important for atherothrombosis pro-
gression [3]. Endothelium regulates vessel wall relax-
ation, thrombosis, and homeostasis by production of
NO [25,39]. Disturbance in NO production facilitates
the aggregation of circulating monocytes/macrophages
into sub-endothelial space and aggravates the instabilityof atherosclerotic plaques [40]. In this study, we found
that CCR5-overexpressing EPCs increased the plaque
content of ECs and the serum level of NO. This may re-
sult from enhanced EPC recruitment to the atheroscler-
otic plaques. The incorporation of EPCs may develop
into ECs, increase the production of NO, and promote
EC regeneration [19,40,41].
Vascular inflammation is involved in the processes of
atherosclerosis and directly induces EC dysfunction
[3,19]. In this study, we found that CCR5-overexpressing
EPCs significantly reduced expression of IL-6 and
MMP9 in the atherosclerotic plaques. CCR5 overexpres-
sion may suppress the production of IL-6 by restoring of
the balance of T helper 17 cells (Th17) and regulatory T
cells (Tregs) [18,42]. Th17/Tregs balance plays a funda-
mental role in the maintenance of the stability of athero-
sclerotic plaques [42,43]. The imbalance of Th17/Tregs
aggravates the burden of plaques by modulation of IL-6
production and increases the risk of plaque rupture
[42,43]. Recent study reported that CCR5 tightly regu-
lates Th17/Tregs balance by modulating the sphingosine
1-phosphate receptor (S1PR)-dependent T-cell egress
process [44-47]. Therefore, administration with CCR5-
overexpressing EPCs may contribute to the restoration of
the Th17/Tregs balance and diminish inflammatory re-
sponses. In the present study, CCR5-overexpressing EPCs
enhanced the EPC recruitment to the atherosclerotic
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granulocyte colony-stimulating factor (G-CSF) signifi-
cantly decreased the levels of MMP9 in atherosclerotic
mice [18], increased EPC recruitment may also suppress
MMP9 expression in the atherosclerotic plaques.
It has been shown that specific interactions between
chemokines and their receptors mediate the chemotaxis
activation of EPCs [12,14,48]. Our in vitro study demon-
strated that CCL5-induced EPC migration was increased by
overexpression of CCR5 and that the increase was abol-
ished by the addition of CCL5 antibody, suggesting that
CCL5/CCR5 interaction is involved in chemotactic effects of
EPCs. This is consistent with previous studies that CCL5
directly induced EPC migration as both [44AANA47]-
RANTES/CCL5 and [E66A]-RANTES/CCL5 mutants dis-
played a reduced ability to induce the migration of EPCs
[15]. CCL5 is highly expressed in atherosclerotic plaques.
Overexpression of CCR5 might promote migration of EPC
toward tissues with higher expression of CCL5 and thus en-
hance EPC recruitment to the atherosclerotic plaques.
Conclusions
In summary, we provided evidence for improving athero-
sclerotic plaque stability through treatment of CCR5-overex-
pressing EPCs. If CCR5 has a similar function in humans,
stimulation of CCR5 expression in EPCs may promote EPC
recruitment, restore EC function, decrease pro-inflamma-
tory factors, and eventually improve the stabilization of ath-
erosclerotic plaques.
Additional files
Additional file 1: Analysis of CCR5 expression in ascending aorta of
humans and mice. (A) Representative images of immunostaining of
CCR5 in non-diseased arteries, advanced plaques, and unstable plaques
in human. (B) Quantitative analysis of CCR5 expression in (A) (n = 3,
*P <0.05, **P <0.01). (C) Representative images of immunostaining of
CCR5 in non-diseased arteries, advanced plaques, and unstable plaques
in ApoE−/− mice. (D) Quantitative analysis of CCR5 expression in (C)
(n = 3, *P <0.05, **P <0.01). Bars represent mean ± standard deviation
(SD). ApoE, apolipoprotein E; CCL5, chemokine (C-C motif) ligand 5; IPH,
thin capped fibroatheroma with intraplaque hemorrhage (advanced
unstable plaques); ND, non-diseased arteries; n.s., non-significant; TfcA,
thick fibrous cap atheroma (advanced stable plaques).
Additional file 2: The efficiency of lentivirus infection in endothelial
progenitor cells (EPCs). (A) Enhanced green fluorescent protein (EGFP)
fluorescence examination of EPCs 72 hours after transfection with Lenti-EGFP
and Lenti-EGFP-CCR5 vector. Arrowheads indicate EGFP-positive cells. Scale
bar = 40 μm. (B) Immunoblots of CCR5 and β-actin of extracts from EPCs
transfected with Lenti-EGFP or Lenti-CCR5.
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